Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1679-1689

  Sieuwerts, Anieta M ^a   Lyng, Maria B ^b   Meijer van Gelder, Marion E ^a   de Weerd, Vanja ^a   Sweep, Fred C G J ^c   Foekens, John A ^a   Span, Paul N ^c   Martens, John W M ^a   Ditzel, Henrik J ^b,d  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Breast cancer; Endocrine therapy; Gene expression; Progression free survival; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; MOLECULAR MARKER; NORADRENALIN TRANSPORTER; PROGESTERONE RECEPTOR; PROTEIN BCL 2; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; AKT1 GENE; ARTICLE; BCAR3 GENE; BCL2 GENE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CDNK1A GENE; CGA GENE; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISTANT METASTASIS; DRUG EFFICACY; EGFR GENE; ESR1 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE SIGNATURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; HUMAN; HUMAN TISSUE; IGF1R GENE; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NAT1 GENE; NCOA1 GENE; NRG1 GENE; PREDICTIVE VALUE; PRIMARY TUMOR; PRKCD GENE; PRKCE GENE; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC THERAPY; TFF1 GENE; TREATMENT RESPONSE;

EID: 84911979255     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.07.003     Document Type: Article

References (39)

1. Al-Mubarak M., Tibau A., Templeton A.J., Cescon D.W., Ocana A., Seruga B., Amir E. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PLoS One 2014, 9:e88238.
2. Albain K.S., Barlow W.E., Shak S., Hortobagyi G.N., Livingston R.B., Yeh I.T., Ravdin P., Bugarini R., Baehner F.L., Davidson N.E., Sledge G.W., Winer E.P., Hudis C., Ingle J.N., Perez E.A., Pritchard K.I., Shepherd L., Gralow J.R., Yoshizawa C., Allred D.C., Osborne C.K., Hayes D.F. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010, 11:55-65. Breast Cancer Intergroup of North, A.
3. Albain K.S., Paik S., van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009, 18(Suppl. 3):S141-S145.
4. Bieche I., Girault I., Urbain E., Tozlu S., Lidereau R. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res. 2004, 6:R252-R263.
5. Chanrion M., Negre V., Fontaine H., Salvetat N., Bibeau F., Mac Grogan G., Mauriac L., Katsaros D., Molina F., Theillet C., Darbon J.M. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin. Cancer Res. 2008, 14:1744-1752.
6. Dorssers L.C., van Agthoven T., Brinkman A., Veldscholte J., Smid M., Dechering K.J. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway. Breast Cancer Res. 2005, 7:R82-R92.
7. Dowsett M., Sestak I., Lopez-Knowles E., Sidhu K., Dunbier A.K., Cowens J.W., Ferree S., Storhoff J., Schaper C., Cuzick J. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J.Clin. Oncol. 2013, 31:2783-2790.
8. Foekens J.A., Portengen H., van Putten W.L., Peters H.A., Krijnen H.L., Alexieva-Figusch J., Klijn J.G. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 1989, 49:5823-5828.
9. Henriksen K.L., Rasmussen B.B., Lykkesfeldt A.E., Moller S., Ejlertsen B., Mouridsen H.T. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 2009, 48:522-531.
10. Hwang K.T., Woo J.W., Shin H.C., Kim H.S., Ahn S.K., Moon H.G., Han W., Park I.A., Noh D.Y. Prognostic influence of BCL2 expression in breast cancer. Int. J. Cancer 2012, 131:E1109-E1119.
11. Kerr D.A., Wittliff J.L. A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen. Horm. Cancer 2011, 2:261-271.
12. Kim S.J., Kang H.S., Jung S.Y., Min S.Y., Lee S., Kim S.W., Kwon Y., Lee K.S., Shin K.H., Ro J. Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. J.Mol. Med. 2010, 88:1123-1131.
13. Kolacinska A., Chalubinska J., Zawlik I., Szymanska B., Borowska-Garganisz E., Nowik M., Fendler W., Kubiak R., Pawlowska Z., Morawiec Z., Szemraj J. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer. Neoplasma 2012, 59:424-432.
14. Larsen M.S., Bjerre K., Giobbie-Hurder A., Laenkholm A.V., Henriksen K.L., Ejlertsen B., Lykkesfeldt A.E., Rasmussen B.B. Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. Acta Oncol. 2012, 51:781-789.
15. Linke S.P., Bremer T.M., Herold C.D., Sauter G., Diamond C. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin. Cancer Res. 2006, 12:1175-1183.
16. Loi S., Haibe-Kains B., Desmedt C., Lallemand F., Tutt A.M., Gillet C., Ellis P., Harris A., Bergh J., Foekens J.A., Klijn J.G., Larsimont D., Buyse M., Bontempi G., Delorenzi M., Piccart M.J., Sotiriou C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J.Clin. Oncol. 2007, 25:1239-1246.
17. Loi S., Haibe-Kains B., Desmedt C., Wirapati P., Lallemand F., Tutt A.M., Gillet C., Ellis P., Ryder K., Reid J.F., Daidone M.G., Pierotti M.A., Berns E.M., Jansen M.P., Foekens J.A., Delorenzi M., Bontempi G., Piccart M.J., Sotiriou C. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239.
18. Lyng M.B., Laenkholm A.V., Tan Q., Vach W., Gravgaard K.H., Knoop A., Ditzel H.J. Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study. PLoS One 2013, 8:e54078.
19. Ma X.J., Wang Z., Ryan P.D., Isakoff S.J., Barmettler A., Fuller A., Muir B., Mohapatra G., Salunga R., Tuggle J.T., Tran Y., Tran D., Tassin A., Amon P., Wang W., Enright E., Stecker K., Estepa-Sabal E., Smith B., Younger J., Balis U., Michaelson J., Bhan A., Habin K., Baer T.M., Brugge J., Haber D.A., Erlander M.G., Sgroi D.C. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616.
20. Mangerini R., Argellati F., Pfeffer U., Boccardo F. Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line. Anticancer Res. 2012, 32:5323-5329.
21. Martens J.W., Nimmrich I., Koenig T., Look M.P., Harbeck N., Model F., Kluth A., Bolt-de Vries J., Sieuwerts A.M., Portengen H., Meijer-Van Gelder M.E., Piepenbrock C., Olek A., Hofler H., Kiechle M., Klijn J.G., Schmitt M., Maier S., Foekens J.A. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res. 2005, 65:4101-4117.
22. Meijer-van Gelder M.E., Look M.P., Peters H.A., Schmitt M., Brunner N., Harbeck N., Klijn J.G., Foekens J.A. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res. 2004, 64:4563-4568.
23. Nehra R., Riggins R.B., Shajahan A.N., Zwart A., Crawford A.C., Clarke R. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J.: Official Publication of the Federation of American Societies for Experimental Biology 2010, 24:2040-2055.
24. Oh M.J., Yi S.J., Kim H.S., Kim J.H., Jeong Y.H., van Agthoven T., Jhun B.H. Functional roles of BCAR3 in the signaling pathways of insulin leading to DNA synthesis, membrane ruffling and GLUT4 translocation. Biochem. Biophys. Res. Commun. 2013, 441:911-916.
25. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007, 12:631-635.
26. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., Cronin M., Baehner F.L., Watson D., Bryant J., Costantino J.P., Geyer C.E., Wickerham D.L., Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J.Clin. Oncol. 2006, 24:3726-3734.
27. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., Quackenbush J.F., Stijleman I.J., Palazzo J., Marron J.S., Nobel A.B., Mardis E., Nielsen T.O., Ellis M.J., Perou C.M., Bernard P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J.Clin. Oncol. 2009, 27:1160-1167.
28. Sestak I., Dowsett M., Zabaglo L., Lopez-Knowles E., Ferree S., Cowens J.W., Cuzick J. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J.Natl. Cancer Inst. 2013, 105:1504-1511.
29. Sgroi D.C., Sestak I., Cuzick J., Zhang Y., Schnabel C.A., Schroeder B., Erlander M.G., Dunbier A., Sidhu K., Lopez-Knowles E., Goss P.E., Dowsett M. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013, 14:1067-1076.
30. Sieuwerts A.M., Meijer-van Gelder M.E., Timmermans M., Trapman A.M., Garcia R.R., Arnold M., Goedheer A.J., Portengen H., Klijn J.G., Foekens J.A. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin. Cancer Res. 2005, 11:7311-7321.
31. Smid M., Wang Y., Zhang Y., Sieuwerts A.M., Yu J., Klijn J.G., Foekens J.A., Martens J.W. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68:3108-3114.
32. Tozlu S., Girault I., Vacher S., Vendrell J., Andrieu C., Spyratos F., Cohen P., Lidereau R., Bieche I. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr. Relat. Cancer 2006, 13:1109-1120.
33. Vaillant F., Merino D., Lee L., Breslin K., Pal B., Ritchie M.E., Smyth G.K., Christie M., Phillipson L.J., Burns C.J., Mann G.B., Visvader J.E., Lindeman G.J. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 2013, 24:120-129.
34. van Agthoven T., Sieuwerts A.M., Meijer-van Gelder M.E., Look M.P., Smid M., Veldscholte J., Sleijfer S., Foekens J.A., Dorssers L.C. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J.Clin. Oncol. 2009, 27:542-549.
35. van Agthoven T., van Agthoven T.L., Dekker A., van der Spek P.J., Vreede L., Dorssers L.C. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J. 1998, 17:2799-2808.
36. van Agthoven T., Veldscholte J., Smid M., van Agthoven T.L., Vreede L., Broertjes M., de Vries I., de Jong D., Sarwari R., Dorssers L.C. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res. Treat. 2009, 114:23-30.
37. Wang X., Belguise K., O'Neill C.F., Sanchez-Morgan N., Romagnoli M., Eddy S.F., Mineva N.D., Yu Z., Min C., Trinkaus-Randall V., Chalbos D., Sonenshein G.E. RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol. Cell Biol. 2009, 29:3832-3844.
38. Wilson A.L., Schrecengost R.S., Guerrero M.S., Thomas K.S., Bouton A.H. Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. PLoS One 2013, 8:e65678.
39. Zhang Y., Sieuwerts A.M., McGreevy M., Casey G., Cufer T., Paradiso A., Harbeck N., Span P.N., Hicks D.G., Crowe J., Tubbs R.R., Budd G.T., Lyons J., Sweep F.C., Schmitt M., Schittulli F., Golouh R., Talantov D., Wang Y., Foekens J.A. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res. Treat. 2009, 116:303-309.